Variantyx · 7 hours ago
Utilization Review Manager- Revenue Cycle Management
United States
Full-time
Remote
Entry, Mid Level
1+ years expVariantyx is a technology-driven precision medicine company providing state-of-the-art diagnostic solutions for the rare genetic disorders and reproductive genetics markets. The Utilization Review Manager is responsible for managing claim denials and appeals for the revenue cycle management team, overseeing workflows, and ensuring compliance with payor policies.
BiotechnologyGeneticsHealth CareHealth DiagnosticsLife Science
Responsibilities
Assist in the development of the Claim rejection and denial Workflows and Standard Operation Procedures (SOPs)
Establish appeal protocols or delegate appropriate follow-up
Develop and maintain templates for appeals
Assist in the development and maintenance of a Payor Guide for the Company focusing on payor policies for medical necessity
Develop and send a monthly revenue cycle management newsletter for the company
Compile and disseminate reports to demonstrate reimbursement of clients and payors
Provide direct management to Claim Specialist
Provide training and support to Prior authorization and Benefits investigation team as needed
Work with Utilization Review Managers to establish team goals and performance metrics
Meet regularly with the Utilization Management team to ensure clean claim submissions
Present eternally and externally regarding billing and reimbursement of genetic testing
Seek out training opportunities for yourself and your team
Qualification
Required
Masters in Genetic Counseling or equivalent training and clinicals experience
Leadership
Attention to detail and organization
At least 1 year of clinical experience in genetics
Board Certified/Board Eligible Genetic Counselor
Company
Variantyx
Variantyx is a molecular diagnostics company specializing in advanced genetic testing and diagnostics.
51-200 employees
Funding
Current Stage
Late StageTotal Funding
$136.5MKey Investors
Kreos CapitalNew Era Capital PartnersBosch Ventures
2025-04-01Series D
2024-04-26Series D· $36M
2023-10-18Series Unknown
Leadership Team
Haim Neerman
Co-Founder and CEO
Tomer Jackman
VP Laboratory Services
Recent News
EIN Presswire
2025-06-21
Company data provided by crunchbase